These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 22926630)

  • 21. ST Segment Elevation ECG Changes During Pharmacologic Stress With Regadenoson.
    Qamruddin S; Huang HW; Mehra A; Bonyadlou S; Yoon AJ
    Clin Nucl Med; 2016 Jan; 41(1):62-4. PubMed ID: 26447370
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic significance of ischemic electrocardiographic changes with regadenoson stress myocardial perfusion imaging.
    Doukky R; Nigatu A; Khan R; Anokwute C; Fughhi I; Ayoub A; Iskander F; Iskander M; Kola S; Sahyouni M; Karavolos K; Hota BN; Gomez J
    J Nucl Cardiol; 2020 Oct; 27(5):1521-1532. PubMed ID: 30132187
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessment of transient ischemic dilation (TID) ratio in gated SPECT myocardial perfusion imaging (MPI) using regadenoson, a new agent for pharmacologic stress testing.
    Katz JS; Ruisi M; Giedd KN; Rachko M
    J Nucl Cardiol; 2012 Aug; 19(4):727-34. PubMed ID: 22527801
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regadenoson: a new myocardial stress agent.
    Al Jaroudi W; Iskandrian AE
    J Am Coll Cardiol; 2009 Sep; 54(13):1123-30. PubMed ID: 19761931
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of body mass index and type of low-level exercise on the side effect profile of regadenoson.
    Salgado-Garcia C; Jimenez-Heffernan A; Lopez-Martin J; Molina-Mora M; Aroui T; Sanchez de Mora E; Ramos-Font C; Rivera de Los Santos F; Ruiz-Frutos C
    Eur J Nucl Med Mol Imaging; 2017 Oct; 44(11):1906-1914. PubMed ID: 28547175
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and feasibility of adjunctive regadenoson injection at peak exercise during exercise myocardial perfusion imaging: The Both Exercise and Regadenoson Stress Test (BERST) trial.
    Ross MI; Wu E; Wilkins JT; Gupta D; Shen S; Aulwes D; Montero K; Holly TA
    J Nucl Cardiol; 2013 Apr; 20(2):197-204. PubMed ID: 23404232
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of regadenoson-induced myocardial creep on dynamic Rubidium-82 PET myocardial blood flow quantification.
    Koenders SS; van Dijk JD; Jager PL; Ottervanger JP; Slump CH; van Dalen JA
    J Nucl Cardiol; 2019 Jun; 26(3):719-728. PubMed ID: 30788758
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety of regadenoson stress testing in patients with pulmonary hypertension.
    Moles VM; Cascino T; Saleh A; Mikhova K; Lazarus JJ; Ghannam M; Yun HJ; Konerman M; Weinberg RL; Ficaro EP; Corbett JR; McLaughlin VV; Murthy VL
    J Nucl Cardiol; 2018 Jun; 25(3):820-827. PubMed ID: 27896702
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regadenoson pharmacologic stress for myocardial perfusion imaging: a three-way comparison between regadenoson administered at peak exercise, during walk recovery, or no-exercise.
    Thompson RC; Patil H; Thompson EC; Thomas GS; Al-Amoodi M; Kennedy KF; Bybee KA; Iain McGhie A; O'Keefe JH; Oakes L; Bateman TM
    J Nucl Cardiol; 2013 Apr; 20(2):214-21; quiz 222-6. PubMed ID: 23233371
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety of regadenoson for vasodilation in cardiac MRI stress tests.
    Bastarrika G; Ezponda A; Baizan AG; Calvo M; Pueyo JC; Gavira JJ; Caballeros M
    Radiologia (Engl Ed); 2020; 62(3):213-221. PubMed ID: 31862182
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The emerging role of the selective A2A agonist in pharmacologic stress testing.
    Gemignani AS; Abbott BG
    J Nucl Cardiol; 2010 Jun; 17(3):494-7. PubMed ID: 20221857
    [No Abstract]   [Full Text] [Related]  

  • 32. Regadenoson for myocardial perfusion imaging: Is it safe?
    Hage FG
    J Nucl Cardiol; 2014 Oct; 21(5):871-6. PubMed ID: 24939324
    [No Abstract]   [Full Text] [Related]  

  • 33. Severe Bradycardia and Asystole Following Regadenoson in Pharmacological Myocardial Perfusion Imaging: Cases and Treatment Recommendations.
    Derbas LA; Thomas GS; Medina CA; Abdel-Karim AA; Saeed IM; Bateman TM
    JACC Cardiovasc Imaging; 2019 Jul; 12(7 Pt 1):1288-1290. PubMed ID: 30878433
    [No Abstract]   [Full Text] [Related]  

  • 34. Safety and tolerability of regadenoson in 514 SPECT MPI patients with and without coronary artery disease and submaximal exercise heart rate response.
    AlJaroudi WA; Alraies MC; Cerquiera MD; Jaber WA
    Eur J Nucl Med Mol Imaging; 2013 Feb; 40(3):341-8. PubMed ID: 23208701
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of the A2a receptor agonist, regadenoson, in modulating hepatic artery flow in the porcine small-for-size liver graft.
    Zhu X; Shiba H; Fung JJ; Wang LF; Arakawa Y; Irefin S; Demetris AJ; Kelly DM
    J Surg Res; 2012 May; 174(1):e37-45. PubMed ID: 22225980
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Myocardial stress perfusion magnetic resonance: initial experience in a pediatric and young adult population using regadenoson.
    Noel CV; Krishnamurthy R; Moffett B; Krishnamurthy R
    Pediatr Radiol; 2017 Mar; 47(3):280-289. PubMed ID: 28035425
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of adenosine signaling in sickle cell therapeutics.
    Field JJ; Nathan DG; Linden J
    Hematol Oncol Clin North Am; 2014 Apr; 28(2):287-99. PubMed ID: 24589267
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quantitative myocardial perfusion positron emission tomography and caffeine revisited with new insights on major adverse cardiovascular events and coronary flow capacity.
    Kitkungvan D; Bui L; Johnson NP; Patel MB; Roby AE; Vejpongsa P; Babar AK; Madjid M; Nacimbene A; Kumar S; DeGolovine A; Gould KL
    Eur Heart J Cardiovasc Imaging; 2019 Jul; 20(7):751-762. PubMed ID: 31056681
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adenosine receptors as drug targets--what are the challenges?
    Chen JF; Eltzschig HK; Fredholm BB
    Nat Rev Drug Discov; 2013 Apr; 12(4):265-86. PubMed ID: 23535933
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serious complications associated with regadenoson administration for myocardial perfusion imaging.
    Kitt T; Jiang J
    J Nucl Cardiol; 2015 Apr; 22(2):395. PubMed ID: 25548120
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.